Coloplast — M&A Activity 2018

Jan 10, 2018

Announcement no. 01/2018 - Coloplast completes acquisition of SAS Lilial

Announcement no. 01/2018 - Coloplast completes acquisition of SAS Lilial

Announcement No. 01/2018         

10 January 2018

Coloplast completes acquisition of SAS Lilial

Coloplast has now completed the acquisition of Lilial.

All terms remain as stated in Coloplast’s stock exchange announcement no. 13/2017 regarding the acquisition of Lilial and Coloplast confirms the previously stated guidance for the financial year 2017/18:

• The organic revenue growth guidance of ~7% is unchanged. The growth in DKK of 5-6% based on spot rates as of 31 October 2017 is expected to be ~1%-points higher.
• The EBIT margin guidance of 31-32% in constant exchange rates and about 31% in DKK is unchanged.

The long-term guidance for the LEAD 20 strategy period until fiscal year-end 2019/20 of 7-9% organic growth p.a. and an EBIT margin of more than 30% in constant currencies is unchanged.

For more information on Lilial please refer to www.lilial.fr.

Lars Rasmussen

President & CEO

For further information, please contact

Investors and analysts

Anders Lonning-Skovgaard

Executive Vice President, CFO

Tel. 4911 1111

Ellen Bjurgert

Director, Investor Relations

Tel. 4911 1800 / 4911 3376

E-mail dkebj@coloplast.com

Press and the media

Lina Danstrup

Senior Media Relations Manager

Tel. 4911 2607

E-mail dklina@coloplast.com

Website

www.coloplast.com

Address

Coloplast A/S

Holtedam 1

DK-3050 Humlebæk

Denmark

CVR NR. 69749917 

This announcement is available in a Danish and an English-language version. In the event of any discrepancies, the Danish version shall prevail.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2018-01 All rights reserved. Coloplast A/S, 3050 Humlebæk, Denmark.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes Ostomy Care, Urology Care, Continence Care and Wound and Skin Care. We operate globally and employ about 11,000 people.

http://prlibrary-eu.nasdaq.com/Resource/Download/59c6e223-2fba-47c6-bafc-71ab4e6b67da